Aurinia Pharmaceuticals Inc. announced that their Phase III trial of voclosporin, an urgently needed treatment for lupus nephritis, has met all primary and secondary endpoints with positive effectiveness and good safety.
Aurinia’s AURORA Phase III clinical trial met its primary endpoint, with 40.8% of patients treated with voclosporin plus standard therapy achieving complete renal response at 52 weeks compared with 22.5 percent of those who received placebo plus standard of therapy. Secondary endpoints showing effectiveness in achieving partial renal response were also significantly better among patients treated with voclosporin than those who received placebo. Voclosporin was also well-tolerated; 20.8 percent of those who received the drug reported serious adverse events versus 21.3 percent of those given placebo. The global, double-blind, placebo-controlled study enrolled 357 patients with active lupus nephritis.
For further information please click here.
